Ocata Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

OCAT 8.56 +0.01 (0.12%)
price chart
Harwood Feffer LLP Announces Investigation of Ocata Therapeutics, Inc.
NEW YORK, Nov. 24, 2015 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Ocata Therapeutics, Inc. ("Ocata" or the "Company") (NASDAQ: OCAT) concerning the proposed acquisition of ...
Ocata Therapeutics (OCAT) to be Acquired by Astellas in $379M Deal
Astellas Pharma Inc. and Ocata Therapeutics, Inc. (NASDAQ: OCAT) announced today that they have entered into a definitive agreement.
Astellas to Acquire Ocata Therapeutics  PR Newswire (press release)
Lessons To Be Learned From Ocata And Others  Seeking Alpha
Analyst Raises FY2015 EPS Estimates for Ocata Therapeutics (OCAT)
Ocata Therapeutics (NASDAQ:OCAT) opened at 8.56 on Friday. The firm's 50-day moving average price is $5.91 and its 200-day moving average price is $5.18.
Traders Are Watching: Synthetic Biologics Inc. (NYSEMKT:SYN), Ocata ...
Synthetic Biologics Inc. (NYSEMKT:SYN) announced that Rhonda Voskuhl, M.D., Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at the University of California, Los Angeles ...
Ocata Therapeutics (OCAT) Forecasted to Post FY2015 Earnings of ($0.67) Per ...  MidSouth Newz
Ocata Therapeutics Reaches New 52-Week High at $8.71 (OCAT)  Putnam Standard
Ocata Therapeutics: Are You Watching A Bluebird Go By?
As you can readily see, since the inception of the company, Bluebird Bio's executives have been granting themselves options and selling their stock with regularity, not unlike Ocata Therapeutics. In fact, it was so prevalent that Seeking Alpha ...
Could Ocata Therapeutics Inc See a Reversal After Breaking Its 52-Week High?
The stock of Ocata Therapeutics Inc (NASDAQ:OCAT) hit a new 52-week high and has $18.96 target or 122.00% above today's $8.54 share price.
Small cap stock picking: CTI BioPharma Corp (NASDAQ:CTIC), Ocata ...  Wall Street Point
Ocata Therapeutics, Inc. (OCAT) Discloses Form 4 Insider Selling : Exec ...  American Trade Journal
DALLAS--(BUSINESS WIRE)--Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Ocata Therapeutics, ...
Ocata Therapeutics (OCAT) Stock Declines After Pricing $30 Million Share Offering
"We rate OCATA THERAPEUTICS INC (OCAT) a SELL. This is based on the dominance of unfavorable investment measures, which should drive this stock to significantly underperform the majority of stocks that we rate.
Midday Watch: Rock Creek (RCPI), Ocata Therapeutics (OCAT), Juno (JUNO ...  Wall Street Pit
Ocata Therapeutics to Ring the NASDAQ Stock Market Opening Bell on June 24, 2015  Business Wire (press release)
Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? (OCAT)
Ocata Therapeutics (NASDAQ:OCAT), formerly named Advanced Cell Technology underwent a major transformation in a short period of time in all aspects of their business.
First Patient Enrolled in Ocata Therapeutics' Phase 2 Study for Dry AMD
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that the first patient has been enrolled in the company's Phase 2 clinical trial using Ocata's ...